x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012932
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG3 |
| Host Species | Mouse |
| Reactivity | Human, Monkey |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to the carboxy terminus of human TRXR2/TXNRD2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TXNRD2 |
| UniProt No. | Q9NNW7 |
| Gene ID | 10587 |
| Gene Description | Thioredoxin reductases are selenoproteins that are critical for maintaining cellular redox balance and eliminating reactive oxygen species. There are three known mammalian thioredoxin reductases: TRXR1/TXNRD1, TRXR2/TXNRD2, and TRXR3/TXNRD3. TRXR2 may function to protect against tumor necrosis factor-α -mediated ROS generation. TRXR2 is critical for normal heart development and function. TRXR2 KO mice experience embryonic lethality, while mitochondrial dysfunction seen in heart-specific TRXR2 KO mice results in congestive heart failure. In humans, certain rare mutations in TRXR2 have been linked to dilated cardiomyopathy. A recent study in the EPIC-Heidelberg cohort shows that serum selenium levels, in concert with certain SNPs in TRXR2 and other selenoproteins, can influence prostate cancer risk. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
